2. Membrane Transporter/Ion Channel Neuronal Signaling Metabolic Enzyme/Protease
  3. GABA Receptor Sodium Channel Cytochrome P450
  4. Denzimol

Denzimol is an orally active anticonvulsant agent. Denzimol inhibits cytochrome P450, and interacts with benzodiazepine receptors. Denzimol selectively antagonizes tonic components of Metrazol-induced seizures in rats and mice. Denzimol can be used for the research of epilepsy and convulsions.

For research use only. We do not sell to patients.

Denzimol

Denzimol Chemical Structure

CAS No. : 73931-96-1

Size Price Stock Quantity
1 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
5 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
10 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
25 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
50 mg Get quote 2 - 3 weeks 1 - 2 weeks 3 - 4 weeks 2 - 3 weeks
100 mg   Get quote  
200 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of Denzimol:

Denzimol Related Antibodies

Top Publications Citing Use of Products

View All Sodium Channel Isoform Specific Products:

View All Isoforms
Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8 Nav1.9

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Denzimol is an orally active anticonvulsant agent. Denzimol inhibits cytochrome P450, and interacts with benzodiazepine receptors. Denzimol selectively antagonizes tonic components of Metrazol-induced seizures in rats and mice. Denzimol can be used for the research of epilepsy and convulsions[1][2][3][4][5][6].

In Vitro

Denzimol binds reversibly to rat liver microsomal cytochrome P450 as a type II ligand with a Ks value of 6.66 mM[1].
Denzimol (10-10-10-4 M; 20 min) inhibits rat liver microsomal Carbamazepine (HY-B0246) 10,11-epoxidation, Diazepam C3-hydroxylation, and Diazepam N1-dealkylation with IC50 values of 4.26 × 10-7 M, 1.44 × 10-6 M, and 6.66 × 10-7 M, respectively[1].
Denzimol does not alter the plasma protein binding of diazepam in pooled rat serum in vitro[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Denzimol Related Antibodies
In Vivo

Denzimol (0.94-15 mg/kg; p.o.; single dose) inhibits hepatic drug metabolism in rats[1].
Denzimol (5 mg/kg; p.o.; single dose; 15 minutes prior to Diazepam injection) significantly increases diazepam plasma and brain concentrations in rats by reducing diazepam's total plasma clearance by ~40%, resulting in an 1.8-fold higher plasma AUC0-t and doubled brain diazepam concentrations[2].
Denzimol (up to 289 mg/kg; i.p.; single dose) selectively antagonizes tonic components of Metrazol-induced seizures in rats, with an ED50 of 2.02 mg/kg for protection against tonic hindpaw extension, and shows no activity against clonic seizures at doses up to 260 mg/kg[4].
Denzimol (up to 182 mg/kg; p.o.; single dose) selectively antagonizes tonic components of Metrazol-induced seizures in mice, with an ED50 of 8.8 mg/kg for protection against tonic hindpaw extension, and shows no activity against clonic seizures at doses up to 182 mg/kg[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-COBS rats (male, 200-300 g)[1]
Dosage: 15 mg/kg (CBZ disposition study); 0.94, 1.87, 3.75, 7.50, 15.0 mg/kg (pentobarbitone sleeping time study)
Administration: p.o.; single dose; 30 minutes before CBZ injection (CBZ disposition study); p.o.; single dose; 1 hour before pentobarbitone injection (pentobarbitone sleeping time study)
Result: Reduced CBZ total plasma clearance from 15.3 mL/min/kg to 9.9 mL/min/kg.
Prolonged CBZ elimination half-life from 83 minutes to 134 minutes.
Caused non-significant increase in CBZ-E elimination half-life from 184 minutes to 240 minutes.
Caused non-significant reductions in CBZ-E peak plasma concentrations from 14 nmol/mL to 11 nmol/mL and time to maximum CBZ-E concentrations from 132 minutes to 202 minutes.
Prolonged pentobarbitone sleeping time.
Achieved an ED50 of 3.0 mg/kg for doubling or more of control sleeping time.
Animal Model: CD-COBS (male, 270-300 g)[2]
Dosage: 5 mg/kg
Administration: p.o.; single dose; 15 minutes prior to diazepam injection
Result: Increased plasma diazepam concentrations throughout the 180-minute sampling period, resulting in a 1.8-fold increase in plasma area under the curve (AUC).
Reduced total plasma clearance of diazepam by ~40%.
Doubled diazepam brain concentrations compared to controls at both 60 minutes and 180 minutes.
Had no significant effect on diazepam's apparent volume of distribution, elimination half-life, or plasma protein binding.
Animal Model: Sprague-Dawley (female, 110-130 g, maximal metrazol/PTZ-induced seizures model)[4]
Dosage: up to 289 mg/kg
Administration: i.p.; single administration
Result: Achieved an ED50 of 2.02 mg/kg for protection against tonic hindpaw extension.
Achieved an ED50 of 22.5 mg/kg for protection against tonic forepaw extension.
Showed no measurable ED50 for protection against twitches/tremors or clonic seizures at doses tested.
Achieved an ED50 of 289 mg/kg for induction of ataxia.
Animal Model: Albino Swiss mice (male, 25-30 g, maximal metrazol/PTZ-induced seizures model)[4]
Dosage: up to 182 mg/kg
Administration: p.o.; single dose
Result: Achieved an ED50 of 8.8 mg/kg for protection against tonic hindpaw extension.
Achieved an ED50 of 20.2 mg/kg for protection against tonic forepaw extension.
Showed no measurable ED50 for protection against twitches/tremors or clonic seizures at doses tested.
Achieved an ED50 of 146.1 mg/kg for induction of ataxia.
Molecular Weight

292.37

Formula

C19H20N2O
CAS No.
SMILES

OC(CN1C=NC=C1)C2=CC=C(CCC3=CC=CC=C3)C=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Denzimol Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Denzimol73931-96-1GABA ReceptorSodium ChannelCytochrome P450Gamma-aminobutyric acid Receptorγ-Aminobutyric acid ReceptorNa channelsNa+ channelsCYPsdiazepamepilepsycarbamazepineratsrat liver microsomesphenytoinbenzodiazepine receptorsrat liver cytochrome P450miceconvulsionsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Denzimol
Cat. No.:
HY-105059
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.